IPA (ImmunoPrecise Antibodies) Debt-to-Equity : 0.50 (As of Oct. 2024)

View and export this data going back to 2011. Start your Free Trial

What is ImmunoPrecise Antibodies Debt-to-Equity?

ImmunoPrecise Antibodies's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Oct. 2024 was $3.46 Mil. ImmunoPrecise Antibodies's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Oct. 2024 was $8.48 Mil. ImmunoPrecise Antibodies's Total Stockholders Equity for the quarter that ended in Oct. 2024 was $23.75 Mil. ImmunoPrecise Antibodies's debt to equity for the quarter that ended in Oct. 2024 was 0.50.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for ImmunoPrecise Antibodies's Debt-to-Equity or its related term are showing as below:

IPA' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.36 Med: 0.13 Max: 0.5
Current: 0.5

During the past 13 years, the highest Debt-to-Equity Ratio of ImmunoPrecise Antibodies was 0.50. The lowest was -0.36. And the median was 0.13.

IPA's Debt-to-Equity is ranked worse than
75.37% of 1007 companies
in the Biotechnology industry
Industry Median: 0.14 vs IPA: 0.50

ImmunoPrecise Antibodies Debt-to-Equity Historical Data

The historical data trend for ImmunoPrecise Antibodies's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ImmunoPrecise Antibodies Debt-to-Equity Chart

ImmunoPrecise Antibodies Annual Data

Trend

Dec14

Dec15

Apr17

Apr18

Apr19

Apr20

Apr21

Apr22

Apr23

Apr24

Debt-to-Equity

Get a 7-Day Free Trial

0.30

0.06

0.04

0.13

0.40

ImmunoPrecise Antibodies Quarterly Data
	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24	Oct24
Debt-to-Equity	Get a 7-Day Free Trial															0.18	0.29	0.40	0.49	0.50

Competitive Comparison of ImmunoPrecise Antibodies's Debt-to-Equity

For the Biotechnology subindustry, ImmunoPrecise Antibodies's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ImmunoPrecise Antibodies's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ImmunoPrecise Antibodies's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where ImmunoPrecise Antibodies's Debt-to-Equity falls into.

Save Embed

;

Save Embed

;

ImmunoPrecise Antibodies Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

ImmunoPrecise Antibodies's Debt to Equity Ratio for the fiscal year that ended in Apr. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.143	+	8.862)	/	24.807
	=	0.40

ImmunoPrecise Antibodies's Debt to Equity Ratio for the quarter that ended in Oct. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(3.456	+	8.482)	/	23.753
	=	0.50

ImmunoPrecise Antibodies (NAS:IPA) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

ImmunoPrecise Antibodies Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of ImmunoPrecise Antibodies's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

ImmunoPrecise Antibodies Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmunoPrecise Antibodies Ltd (NAS:IPA) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

TQB:Germany TQB:Germany

Address

3204 - 4464 Markham Street, Victoria, BC, CAN, V8Z 7X8

Website

https://www.ipatherapeutics.com

ImmunoPrecise Antibodies Ltd is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series proprietary and patented technologies. The company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges.